Circulating sclerostin in disorders of parathyroid gland function

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 12, 2011, Pages 3804-3810

  Costa, Aline G ^a,b   Cremers, Serge ^a   Rubin, Mishaela R ^a   McMahon, Donald J ^a   Sliney Jr , James ^a   Lazaretti Castro, Marise ^b   Silverberg, Shonni J ^a   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; SCLEROSTIN;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPOPARATHYROIDISM; MALE; PARATHYROID DISEASE; PARATHYROID FUNCTION; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ADULT; AGED; BONE DENSITY; BONE MORPHOGENETIC PROTEINS; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; PARATHYROID DISEASES; PARATHYROID GLANDS;

EID: 83155177168     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0566     Document Type: Article

References (34)

1. Parfitt AM 1977 The cellular basis of bone turnover and bone loss: a rebuttal of the osteocytic resorption-bone flow theory. Clin Orthop Relat Res 127:236-247 (Pubitemid 8192287)
2. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW 2004 Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814 (Pubitemid 38375200)
3. Bonewald LF, Johnson ML 2008 Osteocytes, mechanosensing and Wnt signaling. Bone 42:606-615
4. Tanaka K, Yamaguchi Y, Hakeda Y 1995 Isolated chick osteocytes stimulate formation and bone-resorbing activity of osteoclast-like cells. J Bone Miner Metab 13:61-70
5. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J 2005 Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844 (Pubitemid 41598769)
6. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543 (Pubitemid 32184286)
7. Wergedal JE, Veskovic K, Hellan M, Nyght C, Balemans W, Libanati C, Vanhoenacker FM, Tan J, Baylink DJ, Van Hul W 2003 Patients with van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 88:5778-5783 (Pubitemid 38033050)
8. Hamersma H, Gardner J, Beighton P 2003 The natural history of sclerosteosis. Clin Genet 63:192-197 (Pubitemid 36949919)
9. van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW 2005 SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16:319-327 (Pubitemid 40910321)
10. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869 (Pubitemid 351768804)
11. Semënov M, Tamai K, He X 2005 SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 280:26770-26775
12. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CW 2007 Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22:19-28 (Pubitemid 46032593)
13. Johnson ML, Kamel MA 2007 The Wnt signaling pathway and bone metabolism. Curr Opin Rheumatol 19:376-382 (Pubitemid 46884195)
14. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887 (Pubitemid 41379516)
15. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, Hatsell S, Economides AN, Mueller TD, Löwik CW, ten Dijke P 2010 Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem 285:41614-41626
16. Kramer I, Keller H, Leupin O, Kneissel M 2010 Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab 21:237-244
17. Keller H, Kneissel M 2005 SOST is a target gene for PTH in bone. Bone 37:148-158 (Pubitemid 40962421)
18. Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, Bonucci E 2007 Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261-269 (Pubitemid 47106897)
19. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL 2005 Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577-4583 (Pubitemid 41446595)
20. Drake MT, Srinivasan B, Mödder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S 2010 Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056-5062
21. Mödder UI, Clowes JA, Hoey K, Peterson JM, McCready L, Oursler MJ, Riggs BL, Khosla S 2011 Regulation of circulating sclerostin levels by sex steroids in women and in men. J Bone Miner Res 26:27-34
22. Mirza FS, Padhi ID, Raisz LG, Lorenzo JA 2010 Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 95:1991-1997
23. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE 2010 Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 95:2248-2253
24. van Lierop AH, Witteveen JE, Hamdy NA, Papapoulos SE 2010 Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 163:833-837
25. Schett G, Hennies M 2009 Development of a sclerostin ELISA for clinical use. Bone 44:S278
26. Kaji H, Imanishi Y, Sugimoto T, Seino S 2011 Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes 119:440-444
27. Poole KE, Reeve J 2005 Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 5:612-617 (Pubitemid 41614461)
28. Lee SK, Lorenzo JA 1999 Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 140:3552-3561 (Pubitemid 30645409)
29. Mödder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton 3rd LJ, Khosla S 2011 Relation of age, gender, and bone mass to circulating sclerostin levels inwomenand men. J Bone Miner Res 26:373-379
30. Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E 11 January 2011 Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in post-menopausal women-the six-month effect of risedronate and teriparatide. Osteoporos Int doi: 10.1007/s00198-010-1525-6
31. Padhi D, Jang G, Stouch B, Fang L, Posvar E 2011 Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26
32. Rhee Y, Allen MR, Condon K, Lezcano V, Ronda AC, Galli C, Olivos N, Passeri G, O'Brien CA, Bivi N, Plotkin LI, Bellido T 2011 PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J Bone Miner Res 26:1035-1046
33. Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT 2004 FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89:4489-4492 (Pubitemid 39244460)
34. Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT 2007 Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22:931-937